XTX Topco’s Neurogene NGNE Stock Holding History

XTX Topco’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.74M	Buy	55,424 +27,993	+102%	+$771K	0.02%	1250
2026 Q1	$553K	Buy	+27,431	New	+$531K	0.01%	1956
2025 Q4	–	Sell	-12,000	Closed	-$208K	–	3636
2025 Q3	$208K	Buy	+12,000	New	+$241K	0.01%	1816
2025 Q1	–	Sell	-15,256	Closed	-$349K	–	2853
2024 Q4	$349K	Buy	+15,256	New	+$568K	0.03%	1090
2022 Q1	–	Sell	-501	Closed	-$48K	–	870
2021 Q4	$48K	Buy	+501	New	+$61K	0.03%	569

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

XTX Topco's NGNE Position: Q2 2026 in Review

XTX Topco increased its Neurogene (NGNE) stake by 102% in Q2 2026, buying an estimated $771K and bringing the position to 55,424 shares worth $1.74M. The position accounts for 0.02% of the portfolio, ranked #1250.

XTX Topco first reported a position in NGNE in Q4 2021 and has held it in 5 quarters since. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

XTX Topco held 55,424 shares of Neurogene worth $1.74M as of Q2 2026.
XTX Topco bought 27,993 Neurogene shares in Q2 2026, an estimated $771K.
Neurogene made up 0.02% of XTX Topco's portfolio in Q2 2026, its #1250 holding.
XTX Topco first reported a position in Neurogene in Q4 2021 and has held it in 5 quarters since.
112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.